JMP Securities reissued their market outperform rating on shares of LAVA Therapeutics (NASDAQ:LVTX – Free Report) in a report published on Wednesday morning, Benzinga reports. They currently have a $6.00 price objective on the stock.
Separately, HC Wainwright reissued a buy rating and set a $6.00 target price on shares of LAVA Therapeutics in a research note on Friday, June 28th.
Get Our Latest Research Report on LAVA Therapeutics
LAVA Therapeutics Trading Up 1.1 %
LAVA Therapeutics (NASDAQ:LVTX – Get Free Report) last posted its earnings results on Tuesday, August 20th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.05. LAVA Therapeutics had a negative net margin of 228.02% and a negative return on equity of 51.90%. On average, equities analysts forecast that LAVA Therapeutics will post -1.27 earnings per share for the current year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in LAVA Therapeutics stock. Pathway Financial Advisors LLC lifted its stake in LAVA Therapeutics (NASDAQ:LVTX – Free Report) by 328.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 60,000 shares of the company’s stock after acquiring an additional 46,000 shares during the period. Pathway Financial Advisors LLC’s holdings in LAVA Therapeutics were worth $108,000 as of its most recent filing with the Securities and Exchange Commission.
LAVA Therapeutics Company Profile
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.
See Also
- Five stocks we like better than LAVA Therapeutics
- Why Are Stock Sectors Important to Successful Investing?
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- 3 Monster Growth Stocks to Buy Now
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for LAVA Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LAVA Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.